Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AC Immune SA    ACIU   CH0329023102

AC IMMUNE SA (ACIU)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/19/2018 09/20/2018 09/21/2018 09/24/2018 09/25/2018 Date
8.3(c) 8.44(c) 8.6(c) 8.37(c) 8.4 Last
68 124 58 503 80 195 28 248 37 251 Volume
+3.23% +1.69% +1.90% -2.67% +0.36% Change
More quotes
Financials (USD)
Sales 2018 5,97 M
EBIT 2018 -56,4 M
Net income 2018 -58,3 M
Finance 2018 62,7 M
Yield 2018 -
Sales 2019 9,60 M
EBIT 2019 -64,4 M
Net income 2019 -64,4 M
Debt 2019 6,28 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 82,4x
EV / Sales2019 58,4x
Capitalization 555 M
More Financials
Company
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products.It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative... 
More about the company
Surperformance© ratings of AC Immune SA
Trading Rating : - Investor Rating :
More Ratings
Latest news on AC IMMUNE SA
08/20AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzhe..
GL
08/08AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update
GL
07/25New Phase 2 Data Analysis for Crenezumab Presented at Global Alzheimer's Conf..
GL
07/19AC Immune Announces Price of USD 11.75 for Offerings and Issuance of up to 10..
GL
07/17Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited - Updates on AC I..
GL
07/06AC Immune Announces Results of Annual General Meeting
GL
05/02AC Immune Reports First Quarter 2018 Financial Results and Corporate Update
GL
04/05AC Immune Announces the Selection of Tau Small Molecules for Clinical Develop..
GL
03/20AC Immune reports full-year 2017 financial results - successful first year as..
GL
03/15AC Immune prepares for a first in human study of a promising positron emissio..
GL
More news
Sector news : Biotechnology & Medical Research - NEC
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- 2nd Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/14AC Immune $ACIU Downgraded by BidaskClub to Strong Sell  
09/12Get the latest news and updates for $WLTW $VRTV $ACIU $REIS $KAR automaticall.. 
09/11BidaskClub Downgrades AC Immune $ACIU to Strong Sell  
08/30TREND REVERSAL UP ALERT: $ACIU AC IMMUNE SA COMMON ? TradeIdeas via
4
08/30Biggest Breakouts Today  
More tweets
Qtime:15
News from SeekingAlpha
08/24AC Immune holder files to sell 18M shares 
08/22YOUR DAILY PHARMA SCOOP : AC Immune Progresses, Keytruda's Further Approval, Nov.. 
08/20AC Immune advancing anti-Abeta vaccine ACI-24; shares up 1% 
08/08AC Immune reports Q2 results 
08/01Forensic Stock Selections For August - First Year Portfolio +96.80% 
Chart AC IMMUNE SA
Duration : Period :
AC Immune SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AC IMMUNE SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 24,0 $
Spread / Average Target 187%
EPS Revisions
Managers
NameTitle
Andrea Pfeifer CEO, Director & Head-Investor Relations
Martin Velasco Chairman
Jörg Hornstein Chief Financial Officer
Andreas Muhs Chief Scientific Officer
Detlev H. Riesner Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
AC IMMUNE SA-34.61%555
CELLTRION, INC.--.--%33 911
IQVIA HOLDINGS INC31.32%26 045
LONZA GROUP18.19%23 979
INCYTE CORPORATION-29.81%14 132
SEATTLE GENETICS, INC.46.79%12 470